Entity Details
| Primary name |
CNGA1_HUMAN |
| Entity type |
UniProt |
| Source |
Source Link |
Details
| Accession | P29973 |
| EntryName | CNGA1_HUMAN |
| FullName | cGMP-gated cation channel alpha-1 |
| TaxID | 9606 |
| Evidence | evidence at protein level |
| Length | 690 |
| SequenceStatus | complete |
| DateCreated | 1993-04-01 |
| DateModified | 2021-06-02 |
Subcellular Location
Show/Hide Table
| Subcellular Location |
| Cell membrane |
Domains
Show/Hide Table
| Domain | Name | Category | Type |
| IPR000595 | Cyclic nucleotide-binding domain | Domain | Domain |
| IPR005821 | Ion transport domain | Domain | Domain |
| IPR014710 | RmlC-like jelly roll fold | Family | Homologous superfamily |
| IPR018488 | Cyclic nucleotide-binding, conserved site | Site | Conserved site |
| IPR018490 | Cyclic nucleotide-binding-like | Family | Homologous superfamily |
| IPR032406 | Cyclic nucleotide-gated channel, C-terminal leucine zipper domain | Domain | Domain |
| IPR032945 | cGMP-gated cation channel alpha-1 | Family | Family |
Diseases
Show/Hide Table
| Disease ID | Source | Name | Description |
| 613756 | OMIM | Retinitis pigmentosa 49 (RP49) | A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. The disease is caused by variants affecting the gene represented in this entry. |
Drugs
Show/Hide Table
| Drug | Name | Source | Type |
| DB04209 | Dequalinium | Drugbank | small molecule |
Interactions
1 interaction